• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Revvity Announces Financial Results for the Second Quarter of 2024

    7/29/24 6:00:00 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $RVTY alert in real time by email
    • Revenue of $692 million; (2)% reported growth; (1)% organic growth
    • GAAP EPS of $0.45; Adjusted EPS from continuing operations of $1.22
    • Raises full year 2024 adjusted EPS guidance

    Revvity, Inc. (NYSE:RVTY), today reported financial results for the second quarter ended June 30, 2024.

    The Company reported GAAP earnings per share of $0.45, as compared to $0.28 in the same period a year ago. GAAP revenue for the quarter was $692 million, as compared to $709 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $86 million, as compared to $78 million for the same period a year ago. GAAP operating profit margin from continuing operations was 12.4% as a percentage of revenue, as compared to 11.0% in the same period a year ago.

    Adjusted earnings per share from continuing operations for the quarter was $1.22, as compared to $1.21 in the same period a year ago. Adjusted revenue for the quarter was $692 million, as compared to $709 million in the same period a year ago. Adjusted operating income was $199 million, as compared to $204 million for the same period a year ago. Adjusted operating profit margin was 28.7% as a percentage of adjusted revenue, as compared to 28.8% in the same period a year ago.

    Adjustments for the Company's non-GAAP financial measures have been noted in the attached reconciliations.

    "During the second quarter, we celebrated Revvity's one year anniversary with both pride and gratitude for what we have already accomplished as an organization and for our customers," said Prahlad Singh, president and chief executive officer of Revvity. "Our Company's unique strengths of bringing together high levels of continuous innovation and ongoing strong execution enabled us to exceed our expectations, putting us on a good trajectory towards achieving our full year goals."

    Financial Overview by Reporting Segment

    Life Sciences

    • Second quarter 2024 revenue was $314 million, as compared to $336 million in the same period a year ago. Reported revenue decreased 7% and organic revenue decreased 6% as compared to the same period a year ago.
    • Second quarter 2024 adjusted operating income was $112 million, as compared to $128 million in the same period a year ago. Adjusted operating profit margin was 35.8% as a percentage of adjusted revenue, as compared to 38.0% in the same period a year ago.

    Diagnostics

    • Second quarter 2024 revenue was $378 million, as compared to $373 million in the same period a year ago. Reported revenue increased 1% and organic revenue increased 3% as compared to the same period a year ago.
    • Second quarter 2024 adjusted operating income was $98 million, as compared to $85 million in the same period a year ago. Adjusted operating profit margin was 25.9% as a percentage of adjusted revenue, as compared to 22.9% in the same period a year ago.

    Full Year 2024 Guidance

    For the full year 2024, the Company is updating its full year revenue guidance to $2.77-$2.79 billion to reflect recent changes in foreign currency exchange rates and assumes 2% organic revenue growth. The Company is also raising its adjusted EPS guidance to a range of $4.70-$4.80.

    Guidance for the full year 2024 is provided on a non-GAAP basis and cannot be reconciled to the closest GAAP measures without unreasonable effort due to the unpredictability of the amounts and timing of events affecting the items the Company excludes from these non-GAAP measures. The timing and amounts of such events and items could be material to the Company's results prepared in accordance with GAAP.

    Webcast Information

    The Company will discuss its second quarter 2024 results and its outlook for business trends during a webcast on July 29, 2024, at 8:00 a.m. Eastern Time. A live audio webcast and presentation will be available on the Investors section of the Company's website, ir.revvity.com.

    Use of Non-GAAP Financial Measures

    In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), this earnings announcement also contains non-GAAP financial measures. The reasons that we use these measures, a reconciliation of these measures to the most directly comparable GAAP measures, and other information relating to these measures are included below following our GAAP financial statements.

    Factors Affecting Future Performance

    This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities, acquisitions and divestitures. Words such as "believes," "intends," "anticipates," "plans," "expects," "estimates," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) markets into which we sell our products declining or not growing as anticipated; (2) fluctuations in the global economic and political environments; (3) our failure to introduce new products in a timely manner; (4) our ability to execute acquisitions and divestitures, license technologies, or to successfully integrate acquired businesses or licensed technologies into our existing businesses or to make them profitable; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) significant disruption in third-party package delivery and import/export services or significant increases in prices for those services; (8) disruptions in the supply of raw materials and supplies; (9) our ability to retain key personnel; (10) significant disruption in our information technology systems, or cybercrime; (11) our ability to realize the full value of our intangible assets; (12) our failure to adequately protect our intellectual property; (13) the loss of any of our licenses or licensed rights; (14) the manufacture and sale of products exposing us to product liability claims; (15) our failure to maintain compliance with applicable government regulations; (16) our failure to comply with data privacy and information security laws and regulations; (17) regulatory changes; (18) our failure to comply with healthcare industry regulations; (19) economic, political and other risks associated with foreign operations; (20) our ability to obtain future financing; (21) restrictions in our credit agreements; (22) significant fluctuations in our stock price; (23) reduction or elimination of dividends on our common stock; and (24) other factors which we describe under the caption "Risk Factors" in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

    About Revvity

    At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.

    With 2023 revenue of more than $2.7 billion and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 190 countries.

    Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.

    Revvity, Inc. and Subsidiaries

    CONDENSED CONSOLIDATED INCOME STATEMENTS

     

     

     

    Three Months Ended

     

    Six Months Ended

    (In thousands, except per share data)

     

    June 30,

    2024

     

    July 2,

    2023

     

    June 30,

    2024

     

    July 2,

    2023

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Revenue

     

    $

    691,685

     

     

    $

    709,066

     

     

    $

    1,341,605

     

     

    $

    1,383,931

     

     

     

     

     

     

     

     

     

     

    Cost of revenue

     

     

    306,179

     

     

     

    306,735

     

     

     

    601,052

     

     

     

    600,234

     

    Selling, general and administrative expenses

     

     

    251,650

     

     

     

    267,022

     

     

     

    512,221

     

     

     

    515,579

     

    Research and development expenses

     

     

    48,132

     

     

     

    57,253

     

     

     

    98,492

     

     

     

    113,943

     

     

     

     

     

     

     

     

     

     

    Operating income from continuing operations

     

     

    85,724

     

     

     

    78,056

     

     

     

    129,840

     

     

     

    154,175

     

     

     

     

     

     

     

     

     

     

    Interest income

     

     

    (20,512

    )

     

     

    (25,046

    )

     

     

    (40,598

    )

     

     

    (30,318

    )

    Interest expense

     

     

    24,717

     

     

     

    26,007

     

     

     

    49,114

     

     

     

    48,745

     

    Change in fair value of financial securities

     

     

    (7,777

    )

     

     

    2,023

     

     

     

    (6,971

    )

     

     

    (745

    )

    Other expense, net

     

     

    2,634

     

     

     

    3,518

     

     

     

    7,084

     

     

     

    35,499

     

     

     

     

     

     

     

     

     

     

    Income from continuing operations, before income taxes

     

     

    86,662

     

     

     

    71,554

     

     

     

    121,211

     

     

     

    100,994

     

     

     

     

     

     

     

     

     

     

    Provision for income taxes

     

     

    14,056

     

     

     

    12,932

     

     

     

    19,909

     

     

     

    17,527

     

     

     

     

     

     

     

     

     

     

    Income from continuing operations

     

     

    72,606

     

     

     

    58,622

     

     

     

    101,302

     

     

     

    83,467

     

     

     

     

     

     

     

     

     

     

    (Loss) income from discontinued operations

     

     

    (17,246

    )

     

     

    (23,063

    )

     

     

    (19,929

    )

     

     

    521,567

     

     

     

     

     

     

     

     

     

     

    Net income

     

    $

    55,360

     

     

    $

    35,559

     

     

    $

    81,373

     

     

    $

    605,034

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Diluted earnings per share:

     

     

     

     

     

     

     

     

    Income from continuing operations

     

    $

    0.59

     

     

    $

    0.47

     

     

    $

    0.82

     

     

    $

    0.66

     

     

     

     

     

     

     

     

     

     

    (Loss) income from discontinued operations

     

     

    (0.14

    )

     

     

    (0.18

    )

     

     

    (0.16

    )

     

     

    4.14

     

     

     

     

     

     

     

     

     

     

    Net income

     

    $

    0.45

     

     

    $

    0.28

     

     

    $

    0.66

     

     

    $

    4.80

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Weighted average diluted shares of common stock outstanding

     

     

    123,477

     

     

     

    125,398

     

     

     

    123,494

     

     

     

    125,918

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    ABOVE PREPARED IN ACCORDANCE WITH GAAP

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Additional supplemental information (1):

     

     

     

     

     

     

     

     

    (per share, continuing operations)

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    GAAP EPS from continuing operations

     

    $

    0.59

     

     

    $

    0.47

     

     

    $

    0.82

     

     

    $

    0.66

     

    Amortization of intangible assets

     

     

    0.73

     

     

     

    0.74

     

     

     

    1.47

     

     

     

    1.47

     

    Debt extinguishment costs

     

     

    -

     

     

     

    -

     

     

     

    -

     

     

     

    (0.03

    )

    Purchase accounting adjustments

     

     

    0.01

     

     

     

    0.02

     

     

     

    0.06

     

     

     

    0.02

     

    Acquisition and divestiture-related costs

     

     

    0.04

     

     

     

    0.20

     

     

     

    0.11

     

     

     

    0.55

     

    Change in fair value of financial securities

     

     

    (0.06

    )

     

     

    0.02

     

     

     

    (0.06

    )

     

     

    (0.01

    )

    Significant litigation matters and settlements

     

     

    0.05

     

     

     

    -

     

     

     

    0.05

     

     

     

    -

     

    Significant environmental matters

     

     

    -

     

     

     

    -

     

     

     

    -

     

     

     

    0.01

     

    Restructuring and other, net

     

     

    0.08

     

     

     

    0.02

     

     

     

    0.18

     

     

     

    0.04

     

    Tax on above items

     

     

    (0.21

    )

     

     

    (0.25

    )

     

     

    (0.44

    )

     

     

    (0.48

    )

    Significant tax items

     

     

    -

     

     

     

    -

     

     

     

    -

     

     

     

    (0.01

    )

    Adjusted EPS from continuing operations

     

    $

    1.22

     

     

    $

    1.21

     

     

    $

    2.19

     

     

    $

    2.22

     

     

     

     

     

     

     

     

     

     

    (1) amounts may not sum due to rounding

     

     

     

     

     

     

     

     

    Revvity, Inc. and Subsidiaries

    REVENUE AND OPERATING INCOME (LOSS)

     

     

     

    Three Months Ended

     

    Six Months Ended

    (In thousands, except percentages)

     

    June 30,

    2024

     

    July 2,

    2023

     

    June 30,

    2024

     

    July 2,

    2023

     

     

     

     

     

     

     

     

     

    Adjusted revenue and operating income

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Reported revenue

     

    $

    691,685

     

     

    $

    709,066

     

     

    $

    1,341,605

     

     

    $

    1,383,931

     

    Revenue purchase accounting adjustments

     

     

    207

     

     

     

    206

     

     

     

    416

     

     

     

    412

     

    Adjusted revenue

     

     

    691,892

     

     

     

    709,272

     

     

     

    1,342,021

     

     

     

    1,384,343

     

     

     

     

     

     

     

     

     

     

    Reported operating income from continuing operations

     

     

    85,724

     

     

     

    78,056

     

     

     

    129,840

     

     

     

    154,175

     

    OP%

     

     

    12.4

    %

     

     

    11.0

    %

     

     

    9.7

    %

     

     

    11.1

    %

    Amortization of intangible assets

     

     

    90,620

     

     

     

    92,758

     

     

     

    181,858

     

     

     

    184,569

     

    Purchase accounting adjustments

     

     

    623

     

     

     

    2,891

     

     

     

    7,245

     

     

     

    1,977

     

    Acquisition and divestiture-related costs

     

     

    5,779

     

     

     

    28,579

     

     

     

    17,241

     

     

     

    46,530

     

    Significant litigation matters and settlements

     

     

    6,276

     

     

     

    —

     

     

     

    6,276

     

     

     

    —

     

    Significant environmental matters

     

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    1,132

     

    Restructuring and other, net

     

     

    9,845

     

     

     

    2,009

     

     

     

    22,201

     

     

     

    5,104

     

    Adjusted operating income

     

    $

    198,867

     

     

    $

    204,293

     

     

    $

    364,661

     

     

    $

    393,487

     

    OP%

     

     

    28.7

    %

     

     

    28.8

    %

     

     

    27.2

    %

     

     

    28.4

    %

     

     

     

     

     

     

     

     

     

    Segment revenue and segment operating income

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Life Sciences

     

    $

    313,847

     

     

    $

    336,353

     

     

    $

    616,884

     

     

    $

    664,794

     

    Diagnostics

     

     

    378,045

     

     

     

    372,919

     

     

     

    725,137

     

     

     

    719,549

     

    Revenue purchase accounting adjustments

     

     

    (207

    )

     

     

    (206

    )

     

     

    (416

    )

     

     

    (412

    )

    Reported revenue

     

     

    691,685

     

     

     

    709,066

     

     

     

    1,341,605

     

     

     

    1,383,931

     

     

     

     

     

     

     

     

     

     

    Life Sciences

     

    $

    112,401

     

     

    $

    127,759

     

     

    $

    214,126

     

     

    $

    257,218

     

     

     

     

    35.8

    %

     

     

    38.0

    %

     

     

    34.7

    %

     

     

    38.7

    %

    Diagnostics

     

     

    97,915

     

     

     

    85,241

     

     

     

    173,345

     

     

     

    159,673

     

     

     

     

    25.9

    %

     

     

    22.9

    %

     

     

    23.9

    %

     

     

    22.2

    %

    Corporate

     

     

    (11,449

    )

     

     

    (8,707

    )

     

     

    (22,810

    )

     

     

    (23,404

    )

    Subtotal reportable segments operating income

     

     

    198,867

     

     

     

    204,293

     

     

     

    364,661

     

     

     

    393,487

     

     

     

     

     

     

     

     

     

     

    Amortization of intangible assets

     

     

    (90,620

    )

     

     

    (92,758

    )

     

     

    (181,858

    )

     

     

    (184,569

    )

    Purchase accounting adjustments

     

     

    (623

    )

     

     

    (2,891

    )

     

     

    (7,245

    )

     

     

    (1,977

    )

    Acquisition and divestiture-related costs

     

     

    (5,779

    )

     

     

    (28,579

    )

     

     

    (17,241

    )

     

     

    (46,530

    )

    Significant litigation matters and settlements

     

     

    (6,276

    )

     

     

    —

     

     

     

    (6,276

    )

     

     

    —

     

    Significant environmental matters

     

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    (1,132

    )

    Restructuring and other, net

     

     

    (9,845

    )

     

     

    (2,009

    )

     

     

    (22,201

    )

     

     

    (5,104

    )

    Reported operating income from continuing operations

     

    $

    85,724

     

     

    $

    78,056

     

     

    $

    129,840

     

     

    $

    154,175

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    REPORTED REVENUE AND REPORTED OPERATING INCOME (LOSS) PREPARED IN ACCORDANCE WITH GAAP

    Revvity, Inc. and Subsidiaries

    CONDENSED CONSOLIDATED BALANCE SHEETS

       

    (In thousands)

     

    June 30,

    2024

     

    December 31,

    2023

     

     

     

     

     

    Current assets:

     

     

     

     

    Cash and cash equivalents

     

    $

    1,248,120

     

    $

    913,163

    Marketable securities

     

     

    706,070

     

     

    689,916

    Accounts receivable, net

     

     

    597,436

     

     

    632,811

    Inventories, net

     

     

    401,432

     

     

    428,062

    Other current assets

     

     

    205,631

     

     

    337,139

    Total current assets

     

     

    3,158,689

     

     

    3,001,091

     

     

     

     

     

    Property, plant and equipment, net

     

     

    503,119

     

     

    509,654

    Operating lease right-of-use assets, net

     

     

    143,789

     

     

    155,083

    Intangible assets, net

     

     

    2,825,487

     

     

    3,022,321

    Goodwill

     

     

    6,496,971

     

     

    6,533,550

    Other assets, net

     

     

    296,794

     

     

    342,966

    Total assets

     

    $

    13,424,849

     

    $

    13,564,665

     

     

     

     

     

    Current liabilities:

     

     

     

     

    Current portion of long-term debt

     

    $

    711,414

     

    $

    721,872

    Accounts payable

     

     

    174,871

     

     

    204,121

    Accrued expenses and other current liabilities

     

     

    503,728

     

     

    524,470

    Total current liabilities

     

     

    1,390,013

     

     

    1,450,463

     

     

     

     

     

    Long-term debt

     

     

    3,162,600

     

     

    3,177,770

    Long-term liabilities

     

     

    878,788

     

     

    930,946

    Operating lease liabilities

     

     

    123,134

     

     

    132,747

    Total liabilities

     

     

    5,554,535

     

     

    5,691,926

     

     

     

     

     

    Total stockholders' equity

     

     

    7,870,314

     

     

    7,872,739

    Total liabilities and stockholders' equity

     

    $

    13,424,849

     

    $

    13,564,665

     

     

     

     

     

     

     

     

     

     

    PREPARED IN ACCORDANCE WITH GAAP

    Revvity, Inc. and Subsidiaries

    CONSOLIDATED STATEMENTS OF CASH FLOWS

     

     

     

    Three Months Ended

     

    Six Months Ended

     

     

    June 30,

    2024

     

    July 2,

    2023

     

    June 30,

    2024

     

    July 2,

    2023

     

     

    (In thousands)

     

    (In thousands)

     

     

     

     

     

     

     

     

     

    Operating activities:

     

     

     

     

     

     

     

     

    Net income

     

    $

    55,360

     

     

    $

    35,559

     

     

    $

    81,373

     

     

    $

    605,034

     

    Loss (income) from discontinued operations, net of income taxes

     

     

    17,246

     

     

     

    23,063

     

     

     

    19,929

     

     

     

    (521,567

    )

    Income from continuing operations

     

     

    72,606

     

     

     

    58,622

     

     

     

    101,302

     

     

     

    83,467

     

    Adjustments to reconcile income from continuing operations to net cash provided by (used in) continuing operations:

     

     

     

     

     

     

     

     

    Stock-based compensation

     

     

    10,526

     

     

     

    13,633

     

     

     

    22,218

     

     

     

    23,526

     

    Restructuring and other, net

     

     

    9,845

     

     

     

    2,009

     

     

     

    22,201

     

     

     

    5,104

     

    Depreciation and amortization

     

     

    107,344

     

     

     

    108,930

     

     

     

    215,146

     

     

     

    217,938

     

    Change in fair value of contingent consideration

     

     

    176

     

     

     

    2,445

     

     

     

    6,349

     

     

     

    1,085

     

    Amortization of deferred debt financing costs and

    accretion of discounts

     

     

    1,773

     

     

     

    2,026

     

     

     

    3,509

     

     

     

    3,818

     

    Change in fair value of financial securities

     

     

    (7,777

    )

     

     

    2,023

     

     

     

    (6,971

    )

     

     

    (745

    )

    Debt extinguishment gain

     

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    (3,345

    )

    Unrealized foreign exchange (gain) loss

     

     

    (480

    )

     

     

    (2,416

    )

     

     

    (857

    )

     

     

    23,679

     

    Changes in assets and liabilities which provided (used) cash, excluding effects from companies acquired:

     

     

     

     

     

     

     

     

    Accounts receivable, net

     

     

    (8,995

    )

     

     

    (44,640

    )

     

     

    28,194

     

     

     

    (10,216

    )

    Inventories

     

     

    10,042

     

     

     

    (8,255

    )

     

     

    17,251

     

     

     

    (26,775

    )

    Accounts payable

     

     

    (4,747

    )

     

     

    (44,330

    )

     

     

    (22,974

    )

     

     

    (49,225

    )

    Accrued expenses and other

     

     

    (7,985

    )

     

     

    (137,195

    )

     

     

    (52,894

    )

     

     

    (240,285

    )

    Net cash provided by (used in) operating activities of continuing operations

     

     

    182,328

     

     

     

    (47,148

    )

     

     

    332,474

     

     

     

    28,026

     

    Net cash used in operating activities of discontinued operations

     

     

    (23,707

    )

     

     

    (88,171

    )

     

     

    (26,290

    )

     

     

    (99,882

    )

    Net cash provided by (used in) operating activities

     

     

    158,621

     

     

     

    (135,319

    )

     

     

    306,184

     

     

     

    (71,856

    )

     

     

     

     

     

     

     

     

     

    Investing activities:

     

     

     

     

     

     

     

     

    Capital expenditures

     

     

    (22,031

    )

     

     

    (13,949

    )

     

     

    (39,875

    )

     

     

    (34,895

    )

    Purchases of investments and notes receivables

     

     

    (4,000

    )

     

     

    (5,000

    )

     

     

    (4,337

    )

     

     

    (5,000

    )

    Purchases of U.S. Treasury Securities

     

     

    —

     

     

     

    (637,765

    )

     

     

    —

     

     

     

    (831,219

    )

    Proceeds from U.S. Treasury Securities

     

     

    —

     

     

     

    100,000

     

     

     

    —

     

     

     

    100,000

     

    Cash paid for acquisitions, net of cash acquired

     

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    (686

    )

    Net cash used in investing activities of continuing operations

     

     

    (26,031

    )

     

     

    (556,714

    )

     

     

    (44,212

    )

     

     

    (771,800

    )

    Net cash provided by (used in) investing activities of discontinued operations

     

     

    147,522

     

     

     

    (14,327

    )

     

     

    147,522

     

     

     

    2,065,261

     

    Net cash provided by (used in) investing activities

     

     

    121,491

     

     

     

    (571,041

    )

     

     

    103,310

     

     

     

    1,293,461

     

     

     

     

     

     

     

     

     

     

    Financing Activities:

     

     

     

     

     

     

     

     

    Payments of debt financing costs

     

     

    —

     

     

     

    (15

    )

     

     

    —

     

     

     

    (15

    )

    Payments of senior unsecured notes

     

     

    —

     

     

     

    (1,232

    )

     

     

    —

     

     

     

    (50,835

    )

    Net (payments) proceeds on other credit facilities

     

     

    (389

    )

     

     

    (636

    )

     

     

    (11,200

    )

     

     

    7,231

     

    Payments for acquisition-related contingent consideration

     

     

    —

     

     

     

    (8,642

    )

     

     

    (8,749

    )

     

     

    (10,117

    )

    Proceeds from issuance of common stock under stock

    plans

     

     

    2,089

     

     

     

    2,692

     

     

     

    6,032

     

     

     

    3,215

     

    Purchases of common stock

     

     

    (19,553

    )

     

     

    (211,643

    )

     

     

    (30,309

    )

     

     

    (273,299

    )

    Dividends paid

     

     

    (8,642

    )

     

     

    (8,797

    )

     

     

    (17,282

    )

     

     

    (17,638

    )

    Net cash used in financing activities

     

     

    (26,495

    )

     

     

    (228,273

    )

     

     

    (61,508

    )

     

     

    (341,458

    )

     

     

     

     

     

     

     

     

     

    Effect of exchange rate changes on cash, cash equivalents, and restricted cash

     

     

    (3,654

    )

     

     

    (602

    )

     

     

    (12,931

    )

     

     

    (17,571

    )

     

     

     

     

     

     

     

     

     

    Net increase (decrease) in cash, cash equivalents, and restricted cash

     

     

    249,963

     

     

     

    (935,235

    )

     

     

    335,055

     

     

     

    862,576

     

    Cash, cash equivalents, and restricted cash at beginning of period

     

     

    999,465

     

     

     

    2,268,557

     

     

     

    914,373

     

     

     

    470,746

     

    Cash, cash equivalents, and restricted cash at end of period

     

    $

    1,249,428

     

     

    $

    1,333,322

     

     

    $

    1,249,428

     

     

    $

    1,333,322

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Supplemental disclosure of cash flow information:

     

     

     

     

     

     

     

     

    Reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total shown in the consolidated statements of cash flows:

     

     

     

     

     

     

     

     

    Cash and cash equivalents

     

    $

    1,248,120

     

     

    $

    1,331,903

     

     

    $

    1,248,120

     

     

    $

    1,331,903

     

    Restricted cash included in other current assets

     

     

    1,308

     

     

     

    1,062

     

     

     

    1,308

     

     

     

    1,062

     

    Restricted cash included in other assets

     

     

    —

     

     

     

    357

     

     

     

    —

     

     

     

    357

     

    Total cash, cash equivalents and restricted cash

     

    $

    1,249,428

     

     

    $

    1,333,322

     

     

    $

    1,249,428

     

     

    $

    1,333,322

     

     

     

     

     

     

     

     

     

     

     

    PREPARED IN ACCORDANCE WITH GAAP

    Revvity, Inc. and Subsidiaries

    RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (1)

     

     

     

    Continuing Operations

     

     

    Three Months Ended

     

     

    June 30, 2024

    Organic revenue growth:

     

     

    Reported revenue growth from continuing operations

     

    -2%

    Less: effect of foreign exchange rates

     

    -1%

    Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses

     

    0%

    Organic revenue growth from continuing operations

     

    -1%

     

     

     

     

     

     

     

     

    Life Sciences

     

     

    Three Months Ended

     

     

    June 30, 2024

    Organic revenue growth:

     

     

    Reported revenue growth from continuing operations

     

    -7%

    Less: effect of foreign exchange rates

     

    -1%

    Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses

     

    0%

    Organic revenue growth from continuing operations

     

    -6%

     

     

     

     

     

     

     

     

    Diagnostics

     

     

    Three Months Ended

     

     

    June 30, 2024

    Organic revenue growth:

     

     

    Reported revenue growth from continuing operations

     

    1%

    Less: effect of foreign exchange rates

     

    -1%

    Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses

     

    0%

    Organic revenue growth from continuing operations

     

    3%

     

     

     

    (1) amounts may not sum due to rounding

     

     

    Revvity, Inc. and Subsidiaries

    RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (1)

     

     

     

    Continuing Operations

     

     

    Six Months Ended

     

     

    June 30, 2024

    Organic revenue growth:

     

     

    Reported revenue growth from continuing operations

     

    -3%

    Less: effect of foreign exchange rates

     

    -1%

    Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses

     

    0%

    Organic revenue growth from continuing operations

     

    -2%

     

     

     

     

     

     

     

     

    Life Sciences

     

     

    Six Months Ended

     

     

    June 30, 2024

    Organic revenue growth:

     

     

    Reported revenue growth from continuing operations

     

    -7%

    Less: effect of foreign exchange rates

     

    0%

    Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses

     

    0%

    Organic revenue growth from continuing operations

     

    -7%

     

     

     

     

     

     

     

     

    Diagnostics

     

     

    Six Months Ended

     

     

    June 30, 2024

    Organic revenue growth:

     

     

    Reported revenue growth from continuing operations

     

    1%

    Less: effect of foreign exchange rates

     

    -1%

    Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses

     

    0%

    Organic revenue growth from continuing operations

     

    2%

     

     

     

     

     

     

     

     

    Continuing Operations

     

     

    Twelve Months Ended

     

     

    December 29, 2024

     

     

    Projected

    Organic revenue growth:

     

     

    Reported revenue growth from continuing operations

     

    1%

    Less: effect of foreign exchange rates

     

    -1%

    Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses

     

    0%

    Organic revenue growth from continuing operations

     

    2%

     

     

     

    (1) amounts may not sum due to rounding

     

     

    Explanation of Non-GAAP Financial Measures

    We report our financial results in accordance with GAAP. However, management believes that, in order to more fully understand our short-term and long-term financial and operational trends, investors may wish to consider the impact of certain non-cash, non-recurring or other items, which result from facts and circumstances that vary in frequency and impact on continuing operations. Accordingly, we present non-GAAP financial measures as a supplement to the financial measures we present in accordance with GAAP. These non-GAAP financial measures provide management with additional means to understand and evaluate the operating results and trends in our ongoing business by adjusting for certain non-cash expenses and other items that management believes might otherwise make comparisons of our ongoing business with prior periods more difficult, obscure trends in ongoing operations, or reduce management's ability to make useful forecasts. Management believes these non-GAAP financial measures provide additional means of evaluating period-over-period operating performance. In addition, management understands that some investors and financial analysts find this information helpful in analyzing our financial and operational performance and comparing this performance to our peers and competitors.

    We use the term "adjusted revenue" to refer to GAAP revenue, including purchase accounting adjustments for revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules. We use the related term "adjusted revenue growth" to refer to the measure of comparing current period adjusted revenue with the corresponding period of the prior year.

    We use the term "organic revenue" to refer to GAAP revenue, excluding the effect of foreign currency changes and revenue from recent acquisitions and divestitures and including purchase accounting adjustments for revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules. We use the related term "organic revenue growth" to refer to the measure of comparing current period organic revenue with the corresponding period of the prior year.

    We use the term "adjusted gross margin" to refer to GAAP gross margin, excluding amortization of intangible assets and inventory fair value adjustments related to business acquisitions, asset impairments, and including purchase accounting adjustments for revenue from contracts acquired in acquisitions that will not be fully recognized due to business combination accounting rules. We use the related term "adjusted gross margin percentage" to refer to adjusted gross margin as a percentage of adjusted revenue.

    We use the term "adjusted SG&A expense" to refer to GAAP SG&A expense, excluding amortization of intangible assets, purchase accounting adjustments, acquisition and divestiture-related expenses, significant litigation matters and settlements, asset impairments, significant environmental charges, and restructuring and other charges. We use the related term "adjusted SG&A percentage" to refer to adjusted SG&A expense as a percentage of adjusted revenue.

    We use the term "adjusted R&D expense" to refer to GAAP R&D expense, excluding amortization of intangible assets and purchase accounting adjustments. We use the related term "adjusted R&D percentage" to refer to adjusted R&D expense as a percentage of adjusted revenue.

    We use the term "adjusted net interest and other expense" to refer to GAAP net interest and other expense, excluding adjustments for mark-to-market accounting on post-retirement benefits, changes in foreign exchange and interest associated with acquisitions and divestitures, changes in the value of financial securities and debt extinguishment costs.

    We use the term "adjusted operating income" to refer to GAAP operating income, including revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules, and excluding amortization of intangible assets, other purchase accounting adjustments, acquisition and divestiture-related expenses, significant litigation matters and settlements, significant environmental charges, asset impairments, and restructuring and other charges. We use the related terms "adjusted operating profit percentage," "adjusted operating profit margin," or "adjusted operating margin" to refer to adjusted operating income as a percentage of adjusted revenue.

    We use the term "free cash flow" to refer to net cash provided by (used in) operating activities of continuing operations, less payments for additions to property, plant and equipment from continuing operations ("capital expenditures") plus the proceeds from sales of plant, property and equipment from continuing operations ("capital disposals").

    We use the term "adjusted net income," to refer to GAAP income from continuing operations, including revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules, and excluding amortization of intangible assets, debt extinguishment costs, other purchase accounting adjustments, acquisition and divestiture-related expenses, significant litigation matters and settlements, significant environmental charges, changes in the value of financial securities, disposition of businesses and assets, net, changes in foreign exchange and interest associated with acquisitions and divestitures, asset impairments and restructuring and other charges. We also exclude adjustments for mark-to-market accounting on post-retirement benefits, therefore only our projected costs have been used to calculate this non-GAAP measure. We also adjust for any tax impact related to the above items and exclude the impact of significant tax events.

    We use the term "adjusted earnings per share from continuing operations" or "adjusted earnings per share," or "adjusted EPS," to refer to GAAP earnings per share from continuing operations, including revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules, and excluding amortization of intangible assets, debt extinguishment costs, other purchase accounting adjustments, acquisition and divestiture-related expenses, significant litigation matters and settlements, significant environmental charges, changes in the value of financial securities, disposition of businesses and assets, net, changes in foreign exchange and interest associated with acquisitions and divestitures, asset impairments and restructuring and other charges. We also exclude adjustments for mark-to-market accounting on post-retirement benefits, therefore only our projected costs have been used to calculate this non-GAAP measure. We also adjust for any tax impact related to the above items and exclude the impact of significant tax events.

    Management includes or excludes the effect of each of the items identified below in the applicable non-GAAP financial measure referenced above for the reasons set forth below with respect to that item:

    • Amortization of intangible assets—purchased intangible assets are amortized over their estimated useful lives and generally cannot be changed or influenced by management after the acquisition. Accordingly, this item is not considered by management in making operating decisions. Management does not believe such charges accurately reflect the performance of our ongoing operations for the period in which such charges are incurred.
    • Debt extinguishment costs—we incur costs and income related to the extinguishment of debt; including make-whole payments to debt holders, accelerated amortization of debt fees and discounts, and expense or income from hedges to lock in make-whole payments. We exclude the impact of these items from our non-GAAP measures because we believe they do not reflect the performance of our ongoing operations.
    • Revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules—accounting rules require us to account for the fair value of revenue from contracts assumed in connection with our acquisitions. As a result, our GAAP results reflect the fair value of those revenues, which is not the same as the revenue that otherwise would have been recorded by the acquired entity. We include such revenue in our non-GAAP measures because we believe the fair value of such revenue does not accurately reflect the performance of our ongoing operations for the period in which such revenue is recorded.
    • Other purchase accounting adjustments—accounting rules require us to adjust various balance sheet accounts, including inventory, fixed assets and deferred rent balances to fair value at the time of the acquisition. As a result, the expenses for these items in our GAAP results are not the same as what would have been recorded by the acquired entity. Accounting rules also require us to estimate the fair value of contingent consideration at the time of the acquisition, and any subsequent changes to the estimate or payment of the contingent consideration and purchase accounting adjustments are charged to expense or income. We exclude the impact of any changes to contingent consideration from our non-GAAP measures because we believe these expenses or benefits do not accurately reflect the performance of our ongoing operations for the period in which such expenses or benefits are recorded.
    • Acquisition and divestiture-related expenses—we incur legal, due diligence, stay bonuses, incentive awards, stock-based compensation, interest, foreign exchange gains and losses, integration expenses, rebranding expenses, and other costs related to acquisitions and divestitures. We exclude these expenses from our non-GAAP measures because we believe they do not reflect the performance of our ongoing operations.
    • Asset impairments—we incur expense related to asset impairments. Management does not believe such charges accurately reflect the performance of our ongoing operations for the periods in which such charges were incurred.
    • Restructuring and other charges—restructuring and other charges consist of employee severance, other exit costs as well as the cost of terminating certain lease agreements or contracts as well as costs associated with relocating facilities. Management does not believe such costs accurately reflect the performance of our ongoing operations for the period in which such costs are reported.
    • Adjustments for mark-to-market accounting on post-retirement benefits—we exclude adjustments for mark-to-market accounting on post-retirement benefits, and therefore only our projected costs are used to calculate our non-GAAP measures. We exclude these adjustments because they do not represent what we believe our investors consider to be costs of producing our products, investments in technology and production, and costs to support our internal operating structure.
    • Significant litigation matters and settlements—we incur expenses related to significant litigation matters, including the costs to settle or resolve various claims and legal proceedings. Management does not believe such charges accurately reflect the performance of our ongoing operations for the periods in which such charges were incurred.
    • Significant environmental charges—we incur expenses related to significant environmental charges. Management does not believe such charges accurately reflect the performance of our ongoing operations for the periods in which such charges were incurred.
    • Disposition of businesses and assets, net—we exclude the impact of gains or losses from the disposition of businesses and assets from our adjusted earnings per share. Management does not believe such gains or losses accurately reflect the performance of our ongoing operations for the period in which such gains or losses are reported.
    • Impact of foreign currency changes on the current period—we exclude the impact of foreign currency associated with acquisitions and divestitures from these measures by using the prior period's foreign currency exchange rates for the current period because foreign currency exchange rates are subject to volatility and can obscure underlying trends.
    • Impact of significant tax events—we exclude the impact of significant tax events. Management does not believe the impact of significant tax events accurately reflects the performance of our ongoing operations for the periods in which the impact of such events was recorded.
    • Changes in value of financial securities—we exclude the impact of changes in the value of financial securities. Management does not believe such gains or losses accurately reflect the performance of our ongoing operations for the period in which such gains or losses are reported.

    The tax effect for discontinued operations is calculated based on the authoritative guidance in the Financial Accounting Standards Board's Accounting Standards Codification 740, Income Taxes. The tax effect for amortization of intangible assets, inventory fair value adjustments related to business acquisitions, changes to the fair values assigned to contingent consideration, debt extinguishment costs, other costs related to business acquisitions and divestitures, significant litigation matters and settlements, significant environmental charges, changes in the fair value of financial securities, adjustments for mark-to-market accounting on post-retirement benefits, disposition of businesses and assets, net, restructuring and other charges, and the revenue from contracts acquired with various acquisitions is calculated based on operational results and applicable jurisdictional law, which contemplates tax rates currently in effect to determine our tax provision. The tax effect for the impact from foreign currency exchange rates on the current period is calculated based on the average rate currently in effect to determine our tax provision.

    The non-GAAP financial measures described above are not meant to be considered superior to, or a substitute for, our financial statements prepared in accordance with GAAP. There are material limitations associated with non-GAAP financial measures because they exclude charges that have an effect on our reported results and, therefore, should not be relied upon as the sole financial measures by which to evaluate our financial results. Management compensates and believes that investors should compensate for these limitations by viewing the non-GAAP financial measures in conjunction with the GAAP financial measures. In addition, the non-GAAP financial measures included in this earnings announcement may be different from, and therefore may not be comparable to, similar measures used by other companies.

    Each of the non-GAAP financial measures listed above is also used by our management to evaluate our operating performance, communicate our financial results to our Board of Directors, benchmark our results against our historical performance and the performance of our peers, evaluate investment opportunities including acquisitions and discontinued operations, and determine the bonus payments for senior management and employees.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240729804570/en/

    Get the next $RVTY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RVTY

    DatePrice TargetRatingAnalyst
    12/15/2025$110.00Buy → Neutral
    BofA Securities
    12/9/2025$105.00Neutral
    Goldman
    10/16/2025Neutral
    Guggenheim
    5/1/2025$115.00Neutral → Buy
    UBS
    1/10/2025$130.00Outperform → Mkt Perform
    Bernstein
    12/13/2024$138.00Neutral → Buy
    BofA Securities
    10/15/2024$125.00 → $140.00Equal Weight → Overweight
    Barclays
    8/28/2024$130.00Equal Weight
    Wells Fargo
    More analyst ratings

    $RVTY
    SEC Filings

    View All

    SEC Form DEFA14A filed by Revvity Inc.

    DEFA14A - REVVITY, INC. (0000031791) (Filer)

    3/16/26 8:06:48 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form DEF 14A filed by Revvity Inc.

    DEF 14A - REVVITY, INC. (0000031791) (Filer)

    3/16/26 8:01:24 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form PRE 14A filed by Revvity Inc.

    PRE 14A - REVVITY, INC. (0000031791) (Filer)

    3/6/26 4:06:15 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RVTY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Revvity to Present at Upcoming Investor Conferences

    Revvity, Inc. (NYSE:RVTY), today announced it will present at the following investor conferences: Raymond James 47th Annual Institutional Investors Conference Monday, March 2, 2026 7:30 a.m. ET - Max Krakowiak, senior vice president and chief financial officer TD Cowen 46th Annual Health Care Conference Tuesday, March 3, 2026 2:30 p.m. ET - Prahlad Singh, president and chief executive officer Barclays 28th Annual Global Healthcare Conference Tuesday, March 10, 2026 10:30 a.m. ET - Prahlad Singh Attendees will receive an update on the Company and its strategic priorities during fireside chats. Live audio webcasts will be available on the Events section of the Company's website. Rep

    2/17/26 8:00:00 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Revvity Unveils New High-Impact Discovery Platforms and Showcases Recent Innovations at SLAS2026

    New launches in high-content imaging, detection, and automation help labs accelerate drug discovery workflows from sample to insight Revvity, Inc. (NYSE:RVTY) announced the launch of multiple new discovery platforms and technologies at SLAS2026, which are designed to accelerate high-throughput drug discovery workflows. Making their debut at the conference in Boston, February 7-11, are the Opera Phenix OptIQ™ high-content screening system, the EnVision Nexus™ One multimode plate reader, and the AssayMate™ workstation, alongside other recently introduced solutions spanning sample preparation, screening, advanced imaging, and lab automation. At booth #612, Revvity will showcase an expanded

    2/5/26 8:00:00 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2025

    Fourth quarter revenue of $772 million; 6% revenue growth; 4% organic growth Fourth quarter GAAP EPS of $0.87; Adjusted EPS from continuing operations of $1.70 Initiates full year 2026 guidance Revvity, Inc. (NYSE:RVTY) today reported financial results for the fourth quarter and full year ended December 28, 2025. Fourth Quarter 2025 The Company reported GAAP earnings per share of $0.87, as compared to $0.78 in the same period a year ago. Revenue for the quarter was $772 million, as compared to $729 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $112 million, as compared to $119 million for the same period a year ago.

    2/2/26 6:00:00 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RVTY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Gonzales Anita

    4 - REVVITY, INC. (0000031791) (Issuer)

    3/18/26 4:05:13 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Officer Gonzales Anita was granted 1,721 shares, increasing direct ownership by 42% to 5,799 units (SEC Form 4)

    4 - REVVITY, INC. (0000031791) (Issuer)

    3/10/26 4:05:07 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Officer Victor Miriame exercised 1,862 shares at a strike of $95.74 and sold $180,856 worth of shares (1,862 units at $97.13) (SEC Form 4)

    4 - REVVITY, INC. (0000031791) (Issuer)

    2/26/26 4:05:03 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RVTY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Revvity downgraded by BofA Securities with a new price target

    BofA Securities downgraded Revvity from Buy to Neutral and set a new price target of $110.00

    12/15/25 9:57:25 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Goldman initiated coverage on Revvity with a new price target

    Goldman initiated coverage of Revvity with a rating of Neutral and set a new price target of $105.00

    12/9/25 8:53:25 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Guggenheim initiated coverage on Revvity

    Guggenheim initiated coverage of Revvity with a rating of Neutral

    10/16/25 8:27:52 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RVTY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Revvity Inc.

    SC 13G/A - REVVITY, INC. (0000031791) (Subject)

    11/14/24 4:30:07 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Revvity Inc.

    SC 13G/A - REVVITY, INC. (0000031791) (Subject)

    11/14/24 1:28:28 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by Revvity Inc.

    SC 13G - REVVITY, INC. (0000031791) (Subject)

    11/14/24 1:22:34 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RVTY
    Financials

    Live finance-specific insights

    View All

    Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2025

    Fourth quarter revenue of $772 million; 6% revenue growth; 4% organic growth Fourth quarter GAAP EPS of $0.87; Adjusted EPS from continuing operations of $1.70 Initiates full year 2026 guidance Revvity, Inc. (NYSE:RVTY) today reported financial results for the fourth quarter and full year ended December 28, 2025. Fourth Quarter 2025 The Company reported GAAP earnings per share of $0.87, as compared to $0.78 in the same period a year ago. Revenue for the quarter was $772 million, as compared to $729 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $112 million, as compared to $119 million for the same period a year ago.

    2/2/26 6:00:00 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Revvity Board Declares Quarterly Dividend

    The Board of Directors of Revvity, Inc. (NYSE:RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on May 8, 2026 to all shareholders of record at the close of business on April 17, 2026. About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening,

    1/26/26 4:05:00 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Revvity to Hold Earnings Call on Monday, February 2, 2026; Provides Update on Financial Performance

    Revvity, Inc. (NYSE:RVTY), today announced that it will release its fourth quarter and full year 2025 financial results prior to market open on Monday, February 2, 2026. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available on the Investors section of the Company's website. Update on Financial Performance The Company is also providing the following preliminary financial results for the fourth quarter 2025: Reported and organic revenue growth for the fourth

    1/12/26 4:15:00 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials